SCHEMBL25307160

SCHEMBL25307160

C#Cc1ccccc1-c1cc(C#N)ncc1C(=O)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.42
▸ ALDH1A1 P00352 8/20 0.42
▸ L3MBTL1 Q9Y468 4/20 0.41
▸ HSD17B10 Q99714 4/20 0.41
▸ TDP1 Q9NUW8 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HTT P42858 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ GABRP O00591 2/20 0.41
▸ GABRD O14764 2/20 0.41
▸ GABRA1 P14867 2/20 0.41
▸ GABRB1 P18505 2/20 0.41
▸ GABRG2 P18507 2/20 0.41
▸ GABRB3 P28472 2/20 0.41
▸ GABRA5 P31644 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25309295 0.83 NPSR1 (0.48) KDM4EALDH1A1L3MBTL1LMNANPSR1
SCHEMBL25308857 0.82 BRS3 (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31207938 0.82 BRS3 (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31207918 0.75 EIF4E (0.38) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL25308700 0.74 POLQ (0.49) —
SCHEMBL22976470 0.73 KDM4E (0.50) KDM4EALDH1A1L3MBTL1HSD17B10TDP1
SCHEMBL31573596 0.73 KDM4E (0.50) KDM4EALDH1A1L3MBTL1HSD17B10TDP1
SCHEMBL19638940 0.72 TSHR (0.67) KDM4EALDH1A1L3MBTL1HSD17B10TDP1
SCHEMBL22717656 0.72 MEN1 (0.45) KDM4EALDH1A1L3MBTL1TDP1POLB
SCHEMBL31452290 0.72 MEN1 (0.45) KDM4EALDH1A1L3MBTL1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122221-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2025-04-17 — — US disclosed
EP-4464709-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2024-11-20 — — EP disclosed
CN-118525025-A Six-membered cyclothiazole compound and application thereof 南京再明医药有限公司 2024-08-20 — — CN disclosed
WO-2023134739-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF 南京再明医药有限公司 2023-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122221-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF POLRMT, POLQ, POLH KDM4E 2890/4885ALDH1A1 1554/4885L3MBTL1 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback